Back

Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk-equivalent – Results of the Phase 3 ORION-11 trial

2 September 2019 (08:30 - 08:47)
Organised by:
Congress Presentation Part of: Late Breaking Science in Prevention 1 Drug therapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry: analyses from over 55,000 cases and 68 countries
Doctor A. Vallejo-Vaz (Seville, ES)
Presentation thumbnail
New insights into anthropometrics and cardiovascular outcomes in 150 000 adults from 21 countries followed for 9 years: a PURE study
Doctor D. Leong (Hamilton, CA)
Slides Video
Presentation thumbnail
Cardiovascular outcomes in patients with type 2 diabetes and obesity: Comparison of metabolic surgery versus usual care
Doctor A. Aminian (Cleveland, US)
Slides Video

Access the full session

Session thumbnail
Late Breaking Science in Prevention 1

The Event

Event poster

ESC Congress 2019

2 September 2019 08:30 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources